Bio-Path Holdings, Inc.

Equities

BPTH

US09057N4097

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-09 pm EDT			5-day change	1st Jan Change
1.64 ^USD	-8.38%		-11.83%	-82.29%

Jun. 14	Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia At European Hematology Association Congress	CI
Jun. 05	Bio-Path Holdings, Inc. announced that it has received $4.000001 million in funding	CI

Bio-Path Holdings, Inc. announced that it has received $4.000001 million in funding

June 04, 2024

On June 5, 2024, Bio-Path Holdings, Inc closed the transaction. The company has received $3,998,370 from single investor pursuant to exemption provided under Regulation D. Sales commission paid to placement agent $340,000.

Latest news about Bio-Path Holdings, Inc.

Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia At European Hematology Association Congress	Jun. 14	CI
Bio-Path Holdings, Inc. announced that it has received $4.000001 million in funding	Jun. 04	CI
Bio-Path Holdings, Inc. announced that it expects to receive $4.000001 million in funding	Jun. 03	CI
Sector Update: Health Care Stocks Gain Late Afternoon	Jun. 03	MT
Top Midday Gainers	Jun. 03	MT
Wall Street Set to Open Slightly Higher Monday as Investors Await Key Manufacturing Data for May	Jun. 03	MT
Investors Await Key Manufacturing Data as US Futures Nudge Higher in Monday's Premarket Session	Jun. 03	MT
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia At American Society of Clinical Oncology Annual Meeting	Jun. 03	CI
Transcript : Bio-Path Holdings, Inc., Q1 2024 Earnings Call, May 15, 2024	May. 15
Bio-Path Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 14	CI
Bio-Path Closes $1.2 Million Share Offering	Apr. 19	MT
Bio-Path Holdings, Inc. Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1B Clinical Trial of Bp1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients	Apr. 18	CI
Bio-Path Holdings, Inc. Expands Global Patent Portfolio	Apr. 15	CI
North American Morning Briefing : Investors on Edge as High-Stakes Jobs Report Awaited	Apr. 05	DJ
Transcript : Bio-Path Holdings, Inc., Q4 2023 Earnings Call, Mar 08, 2024	Mar. 08
North American Morning Briefing : Stock Futures -2-	Mar. 08	DJ
Bio-Path Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07	CI
Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia Patients	Jan. 10	CI
Bio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1B Clinical Trial of Bp1002 in Refractory/Relapsed Acute Myeloid Leukemia	Dec. 14	CI
Transcript : Bio-Path Holdings, Inc., Q3 2023 Earnings Call, Nov 15, 2023	Nov. 15
North American Morning Briefing : Stocks Seen -2-	Nov. 15	DJ
Bio-Path Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Certain Warrants of Bio-Path Holdings, Inc. are subject to a Lock-Up Agreement Ending on 1-NOV-2023.	Oct. 31	CI
Certain Options of Bio-Path Holdings, Inc. are subject to a Lock-Up Agreement Ending on 1-NOV-2023.	Oct. 31	CI
Certain Common Stock of Bio-Path Holdings, Inc. are subject to a Lock-Up Agreement Ending on 1-NOV-2023.	Oct. 31	CI

Chart Bio-Path Holdings, Inc.

Duration

Period

More charts

Company Profile

Bio-Path Holdings, Inc. is a biotechnology company. The Company is engaged in developing DNAbilize, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. DNAbilize, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the bodyâs enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. Its lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase II study for blood cancers, and BP1001-A, a drug product modification of prexigebersen, is in a Phase I/Ib study for solid tumors. The Companyâs second product, BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including lymphoma and acute myeloid leukemia. BP1003 is its third liposome delivered antisense drug candidate.

Sector

Biotechnology & Medical Research

Calendar

2024-08-12 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.64 USD

Average target price

20 USD

Spread / Average Target

+1,119.51%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BIO-PATH HOLDINGS, INC.	-82.29%	3.72M
MODERNA, INC.	+16.71%	44.63B
LONZA GROUP AG	+42.66%	40.46B
IQVIA HOLDINGS INC.	-7.92%	38.07B
ALNYLAM PHARMACEUTICALS, INC.	+33.09%	32.27B
CELLTRION, INC.	-7.10%	27.3B
ICON PUBLIC LIMITED COMPANY	+14.46%	26.53B
UNITED THERAPEUTICS CORPORATION	+46.73%	14.06B
MEDPACE HOLDINGS, INC.	+34.07%	12.54B
BIO-TECHNE CORPORATION	-7.61%	11.28B

Other Biotechnology & Medical Research